Review Article

Emerging Biomarkers in Non–Small Cell Lung Cancer

Melinda Oliver, BA, BSN, RN, MPAP

The University of Texas MD Anderson Cancer Center, Houston, Texas

Author’s disclosures of potential conflicts of interest are found at the end of this article.

Melinda Oliver, BA, BSN, RN, MPAP, The University of Texas MD Anderson Cancer Center—Thoracic Medical Oncology, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030. E-mail: mroliver@mdanderson.org


J Adv Pract Oncol 2017;8:51–58 | https://doi.org/10.6004/jadpro.2017.8.5.16 | © 2017 Harborside Press®


  

ABSTRACT

Since the identification of epidermal growth factor receptor (EGFR) mutations in a subset of non–small cell lung cancers and the concomitant success of front-line EGFR inhibitors in treating cancers with these mutations, interest in identifying further significant oncogenic driver mutations or biomarkers has increased. Current mutations under consideration include BRAF, MET, RET, and HER2. This article discusses the current research into these biomarkers and the significance of biomarkers for treating NSCLC.




For access to the full length article, please sign in.

Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.